Created at Source Raw Value Validated value
June 25, 2024, noon usa

inclusion criteria: 1. clinically healthy children 12-17 years of age. 2. subjects who have previously received complete primary series of inactivated (sinovac®) covid-19 vaccine with the last dose administered a minimum of 6 months prior to inclusion but not longer than 12 months prior to inclusion. 3. parent/legal guardian and subject has been informed properly regarding the study, and signed the informed consent form (parent/legal guardian) and assent form (subject). 4. parent and/or legal guardian will commit to comply with the instructions of the investigator and the schedule of the trial.

inclusion criteria: 1. clinically healthy children 12-17 years of age. 2. subjects who have previously received complete primary series of inactivated (sinovac®) covid-19 vaccine with the last dose administered a minimum of 6 months prior to inclusion but not longer than 12 months prior to inclusion. 3. parent/legal guardian and subject has been informed properly regarding the study, and signed the informed consent form (parent/legal guardian) and assent form (subject). 4. parent and/or legal guardian will commit to comply with the instructions of the investigator and the schedule of the trial.

Feb. 15, 2023, noon usa

inclusion criteria: clinically healthy children 12-17 years of age. subjects who have previously received complete primary series of inactivated (sinovac®) covid-19 vaccine with the last dose administered a minimum of 6 months prior to inclusion but not longer than 12 months prior to inclusion. parent/legal guardian and subject has been informed properly regarding the study, and signed the informed consent form (parent/legal guardian) and assent form (subject). parent and/or legal guardian will commit to comply with the instructions of the investigator and the schedule of the trial.

inclusion criteria: clinically healthy children 12-17 years of age. subjects who have previously received complete primary series of inactivated (sinovac®) covid-19 vaccine with the last dose administered a minimum of 6 months prior to inclusion but not longer than 12 months prior to inclusion. parent/legal guardian and subject has been informed properly regarding the study, and signed the informed consent form (parent/legal guardian) and assent form (subject). parent and/or legal guardian will commit to comply with the instructions of the investigator and the schedule of the trial.